Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;40(4):965-972.
doi: 10.1007/s00345-021-03923-y. Epub 2022 Jan 13.

Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review

I Latorzeff  1 , G Ploussard  2 , M D Faye  3 , U Schick  4 , N Benziane-Ouaritini  5 , T M Niazi  3 , F Saad  6 , P Sargos  5
Affiliations
Review

Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review

I Latorzeff et al. World J Urol. 2022 Apr.

Abstract

Introduction: The management of the postoperative biological relapse of prostate cancer is most often based on salvage radiotherapy (SRT) with or without the addition of a variable duration of hormone therapy (HT). The indications for SRT +/- HT are established in the setting of a rising PSA level after a period where an undetectable PSA was achieved. However, in case of detectable PSA immediately after radical prostatectomy, the treatment options and prognosis are still unclear.

Materials and methods: We conducted a narrative review based on an analysis of the literature focusing on articles targeting the population of patients with postoperative persistently detectable PSA level. Case reports, original articles, clinical trials, and published reviews were studied for this purpose.

Conclusion: This article will describe current management of patients with detectable PSA immediately after radical prostatectomy, notably the contribution of modern imaging and new treatment options involving the combination of RT and HT.

Keywords: Clinical trials; Detectable persistent PSA; Prostate cancer; Salvage radiation therapy; Salvage radiotherapy; pN0 patients.

PubMed Disclaimer

References

    1. Ploussard G, Fossati N, Wiegel T, D’Amico A, Hofman MS, Gillessen S et al (2021) Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature. Eur Urol Oncol 4(2):150–169 - DOI
    1. Ravery V (1999) The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 17(3):127–129 - PubMed
    1. Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M et al (2019) Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol 76(1):106–114 - DOI
    1. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Pozzo LD et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578 - DOI
    1. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN (2012) Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 48:837–44 - DOI

Substances

LinkOut - more resources